Range Cancer Therapeutics ETF (E18B)
XMUN 
Summary
E18B Chart
4 Solid ETFs Under $20 for Your Portfolio
Low-priced ETFs could be attractive for investors as these enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.
Best-Performing ETF Areas of Past Week
Wall Street was upbeat last week on Fed rate cut hopes.
5 Top-Ranked ETFs to Buy at a Bargain
After a three-day rout, Wall Street staged a solid comeback as investors bought beaten-down stocks and recession fears eased. To tap the beaten-down prices, we have highlighted five ETFs from different corners that have declined over the past week and have a solid Zacks ETF Rank.
Range Cancer Therapeutics ETF (E18B) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Range Cancer Therapeutics ETF ever had a stock split?
Range Cancer Therapeutics ETF Profile
| XMUN Exchange | US Country |
Overview
Established in 2023 by Range Fund Holdings, the index is a dedicated financial instrument focused on the pharmaceutical and biotechnology sectors within the United States. Specifically, it engages in tracking the performance of a meticulously curated portfolio. This portfolio consists of U.S. exchange-listed stocks of pharmaceutical or biotechnology companies, as well as American Depositary Receipts (ADRs), all of which must boast a market capitalization exceeding the $250 million threshold. The essence of this index is rooted in its investment strategy, aspiring to allocate all or a significant majority of its assets into the component securities that constitute the index, thereby offering a concentrated exposure to the sector's dynamics and performance.
Products and Services
The main offerings of the index can be broken down into two broad categories:
- Investment in Pharmaceutical and Biotechnology Stocks
This pertains to investing directly in stocks of pharmaceutical and biotechnology companies listed on U.S. exchanges. These companies are meticulously chosen based on their market capitalization, which must be over $250 million. This strategy aims to tap into the growth potential and innovations within the healthcare and life sciences sectors, leveraging advances in medicine and technology to achieve potential returns on investment.
- Investment in American Depositary Receipts (ADRs)
ADRs represent a significant component of the portfolio, providing investors an opportunity to gain exposure to foreign pharmaceutical and biotechnology firms that meet the index's criteria but are listed on U.S. exchanges. This diversifies the investment scope beyond domestic companies, enabling an engagement with the global market dynamics and advancements in the pharmaceutical and biotechnology industries worldwide. ADRs offer a practical solution for investors looking to benefit from international companies' growth while mitigating some of the complexities associated with direct investments in foreign stock exchanges.
